pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
Acadia Pharmaceuticals projects
4 ClinicalTrials.gov programs sponsored by Acadia Pharmaceuticals.
Acadia Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
L. helveticus R0052 and B. longum R0175
Acadia Pharmaceuticals B.V.
Attention Deficit Hyperactivity Disorder
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Insomnia Chronic
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Neurodegenerative Diseases
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Parkinson Disease Psychosis
1 trial
Frequently asked questions
How many clinical projects does Acadia Pharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.